CN103772220A - Novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and application thereof - Google Patents

Novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and application thereof Download PDF

Info

Publication number
CN103772220A
CN103772220A CN201310646191.4A CN201310646191A CN103772220A CN 103772220 A CN103772220 A CN 103772220A CN 201310646191 A CN201310646191 A CN 201310646191A CN 103772220 A CN103772220 A CN 103772220A
Authority
CN
China
Prior art keywords
medicine
ethyl
dimethylamino
hexalin
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310646191.4A
Other languages
Chinese (zh)
Inventor
陈兴海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHENJIANG SHENG'AN PHARMACEUTICAL CO Ltd
Original Assignee
ZHENJIANG SHENG'AN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHENJIANG SHENG'AN PHARMACEUTICAL CO Ltd filed Critical ZHENJIANG SHENG'AN PHARMACEUTICAL CO Ltd
Priority to CN201310646191.4A priority Critical patent/CN103772220A/en
Publication of CN103772220A publication Critical patent/CN103772220A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and an application thereof. The derivative is good in medicine activity, and can be used for greatly prolonging the half life of a medicine, prolonging the time of the medicine staying in a human body and increasing the concentration of the medicine in blood, so that a better curative effect can be achieved. The half life of the medicine is greatly prolonged, so that the active concentration of the medicine can be kept in blood for a longer time, and the dosage of the medicine can be reduced while the curative effect is maintained under a dosage limited treatment condition. According to the derivative, adverse metabolism problems of the medicine can be solved, the medicine toxicity can be reduced, and the toxic and side effects in the administration process can be reduced.

Description

1-[2-dimethylamino-1-(4-p-methoxy-phenyl) ethyl] new derivatives and the application thereof of hexalin
Technical field
The present invention relates to a kind of derivative and application thereof of compound, belong to technical field of pharmaceuticals.
Background technology
Major depressive disorder (MDD), is often called depression, is a kind of mental disorder, and major depressive disorder can disable and make people's function undesired.According to World Health Organization prediction, to the year two thousand thirty dysthymia disorders will become disabled major cause.Be characterized in that emotional change and other symptoms interference people work, sleep, learn, have a meal and enjoy happy movable ability.In people's life cycle, can often recur dysthymia disorders, some people may only stand 1 dysthymia disorders and occur.Other S&Ss of MDD comprise daily routines forfeiture interest; body weight or be suitable for noticeable change; insomnia or hypersomnia (drowsiness); restless/walking (psychomotor agitation); tired increasing; sense of guilt or valueless sense, thought is slow or attention is impaired and suicide purpose or suicide idea etc., is not that all people that have dysthymia disorders stand identical symptom.Venlafaxine is serotonin-NRI class thymoleptic, is to be released the medicine that is used for the treatment of major depressive disorder and generalized anxiety disorder disease of now being produced by Pfizer company in 1993 by Wyeth.Its chemical name is: 1-[2-dimethylamino-1-(4-p-methoxy-phenyl) ethyl] hexalin.The multinomial relatively research of Venlafaxine curative effect all thinks that this medicine Cure of depression is evident in efficacy, this medicine is mainly by block the re-uptake of NE and 5-HT simultaneously, thereby rising NE and 5-HT concentration are brought into play dual antidepressant effect, there are some researches show, this medicine can make normal people's attention concentrate, memory, fast reaction speed, improve intelligence, and main drive parameter and a series of psychomotor are all had no significant effect, but affect vigilance.For depressive patients, after general medication 1-2 week can there is obvious antidepressant effect in (also having in 4 days).Due in the time using Venlafaxine to treat, conventionally strengthen dosage in order to reach result for the treatment of, cause producing a lot of poor metabolism problems, the active metabolite producing by bad metabolic reaction due to medicine normally medicine produces the important factor of toxicity and other side effects, thereby can produce more side effect to human body in therapeutic process, use the common adverse reactions that can make patient produce in venlafaxine process to have: gastrointestinal discomfort is as felt sick, dry, apocleisis, constipation and vomiting, central nervous system is abnormal as dizzy, drowsiness, dreamland is strange, insomnia and nervous, visual abnormality, yawn, perspiration and sexual function are abnormal as impotence, abnormal and the sexual desire reduction of ejaculation.Accidental untoward reaction is: unable, inflatable, tremble, exciting, diarrhoea and rhinitis.
Summary of the invention
The object of the invention is to overcome defect of the prior art, 1-[2-dimethylamino-1-(4-p-methoxy-phenyl is provided) ethyl] new derivatives and the application thereof of hexalin, the pharmaceutical activity of described derivative is good, the bad metabolic problems that can solve medicine simultaneously, the toxic side effect in medication process is little.
The present invention is achieved by the following technical programs.
1-[2-dimethylamino-1-(4-p-methoxy-phenyl) ethyl] new derivatives of hexalin, there is the following chemical structure general formula:
Figure BDA0000429097730000031
R in formula 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14r 15, R 16, R 17, R 18, R 19be hydrogen or deuterium or fluorine independently, wherein have one at least for deuterium or fluorine.
Above-mentioned 1-[2-dimethylamino-1-(4-p-methoxy-phenyl) ethyl] new derivatives of hexalin, wherein, R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14r 15, R 16, R 17, R 18, R 19in one or several is fluorine.
Above-mentioned 1-[2-dimethylamino-1-(4-p-methoxy-phenyl) ethyl] new derivatives of hexalin, wherein, R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14r 15, R 16, R 17, R 18, R 19in one or several is deuterium.
Above-mentioned 1-[2-dimethylamino-1-(4-p-methoxy-phenyl) ethyl] application of new derivatives of hexalin, the application of described derivative in the medicine of preparing Cure of depression and anxiety disorder disease.
1-[2-dimethylamino-1-(4-p-methoxy-phenyl of the present invention) ethyl] new derivatives of hexalin can be used as the activeconstituents of the medicine of Cure of depression and anxiety disorder disease, in this medicine, also can contain described derivative and pharmaceutically acceptable carrier or the figuration body of significant quantity, make the formulation that is applicable to use.Drug delivery system can be albumin bound type injection liquid, liposome, powder pin, nanoparticle and cyclodextrin inclusion compound etc., form of administration can be injection liquid, also can be solid dosage or semisolid dosage form, as being injection, tablet, wafer, pill, powder or granule etc.
1-[2-dimethylamino-1-(4-p-methoxy-phenyl of the present invention) ethyl] new derivatives of hexalin can be made into the pharmaceutically acceptable salt that is suitable as medicine, the pharmaceutically acceptable salt that is suitable as medicine refers to the salt that is suitable as medicine that derivative of the present invention and acid or alkali form, and comprises inorganic salt and organic salt.The preferred salt of one class is derivative of the present invention and the sour salt forming.The acid that is applicable to formation salt includes, but are not limited to: the mineral acids such as hydrochloric acid, Hydrogen bromide, hydrofluoric acid, sulfuric acid, nitric acid and phosphoric acid, the organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, propanedioic acid, succsinic acid, fumaric acid, toxilic acid, lactic acid, oxysuccinic acid, tartrate, citric acid, picric acid, methylsulfonic acid, benzene methanesulfonic acid and Phenylsulfonic acid; And the acidic amino acid such as aspartic acid, L-glutamic acid.
1-[2-dimethylamino-1-(4-p-methoxy-phenyl of the present invention) ethyl] new derivatives of hexalin is compared with Venlafaxine of the prior art, and tool has the following advantages:
(1) better efficacy of derivative of the present invention, it can increase the transformation period of medicine greatly, the time that prolong drug is detained at human body Inner, improves the concentration of blood Chinese traditional medicine simultaneously, thereby reaches better curative effect.
(2) the drug use dosage of derivative of the present invention is less, thereby can eliminate the bad metabolic problems of medicine, because the transformation period of medicine greatly increases and makes medicine can keep for more time active concentration in blood, make under the treatment condition that has dose limitation, the using dosage that can reduce medicine in keeping curative effect, reduces drug toxicity.
(3) toxicity of derivative of the present invention, side effect are still less, the active metabolite producing by bad metabolic reaction due to medicine normally medicine produces the important factor of toxicity and other side effects, eliminate the bad metabolic problems of medicine, greatly reduced toxicity and other side effects of medicine.
Embodiment
By specific embodiment, the specific embodiment of the present invention is described in further detail below.
Embodiment 1
Preparation 1-[2-dimethylamino-1-(4-Trifluoromethoxyphen-l)-ethyl]-hexalin.
The preparation of the derivative of the present invention three-step reaction that comprises condensation, reduces and methylate:
Reaction equation is as follows:
Figure BDA0000429097730000051
Preparation process is as follows:
(1) condensation reaction preparation (1-hydroxy-cyclohexyl)-(4 – Trifluoromethoxyphen-l) acetonitrile (1-1):
Under anhydrous and oxygen-free argon shield; the sodium hydroxide of hydrogen sulfate-tetra-n-butyl ammonium and 2mol/L is added successively in (4-Trifluoromethoxyphen-l) acetonitrile; 0 ℃ and stir under reaction keep 30min; then at 0-5 ℃, in 10min, pimelinketone is joined in this mixture; reaction mixture is warming up to room temperature vigorous stirring 1h; white depositions is filtered; wash with water and hexane wash-out, obtaining required product (1-hydroxy-cyclohexyl)-(4 – Trifluoromethoxyphen-l) acetonitrile (1-1) is white solid.(4-Trifluoromethoxyphen-l) acetonitrile and pimelinketone, the mole ratio of sodium hydroxide and hydrogen sulfate-tetra-n-butyl ammonium is 1 ︰ 1-1.2 ︰ 1.2-1.3 ︰ 0.1.
(2) reduction reaction is prepared 1-[2-amino-1-(4-Trifluoromethoxyphen-l)-ethyl]-hexalin (1-2).
Under anhydrous and oxygen-free hydrogen shield; in the methanol solution of (4-Trifluoromethoxyphen-l) acetonitrile, add nickel catalyzator; reaction mixture is warming up to room temperature vigorous stirring 1-4h; by white depositions filtering and concentrating, thick product obtains product 1-[2-amino-1-(4-Trifluoromethoxyphen-l through purification by silica gel column chromatography)-ethyl]-hexalin (1-2).The mole ratio of (4-Trifluoromethoxyphen-l) acetonitrile and nickel catalyzator is 1 ︰ 0.1-0.2.1 molar (4-Trifluoromethoxyphen-l) acetonitrile uses the methyl alcohol of 2-5L.
(3) methylation reaction is prepared 1-[2-dimethylamino-1-(4-Trifluoromethoxyphen-l)-ethyl]-hexalin.
Under anhydrous and oxygen-free argon shield, methyl iodide and salt of wormwood are at room temperature joined to 1-[2-amino-1-(4-Trifluoromethoxyphen-l)-ethyl]-hexalin is in the solution of anhydrous tetrahydro furan, at room temperature stir 20h, reaction mixture is diluted with tetrahydrofuran (THF), filter, by filtrate vacuum concentration, add again 3-amino-1-propyl alcohol (1mL), mixture is cooled to room temperature after stirring reaction 4h at 170 ℃, dilute with water, and be extracted with ethyl acetate, by the organic layer salt water washing merging, dry also concentrating under reduced pressure, thick product obtains target product 1-[2-dimethylamino-1-(4-Trifluoromethoxyphen-l through purification by silica gel column chromatography)-ethyl]-hexalin.1-[2-amino-1-(4-Trifluoromethoxyphen-l)-ethyl] mole ratio of-hexalin and methyl iodide and salt of wormwood is 1 ︰ 6-7 ︰ 3-4.1 molar 1-[2-amino-1-(4-Trifluoromethoxyphen-l)-ethyl]-hexalin uses the tetrahydrofuran (THF) of 2-5L, 3-amino-1-propyl alcohol of 0.2-0.3L and the salt solution of 2-5L.
Embodiment 2
Preparation 1-[2-dimethylamino-1-(4-Trifluoromethoxyphen-l)-ethyl]-hexalin-d6.
Preparation method, with embodiment 1, replaces with methyl iodide-d3 by the methyl iodide in embodiment 1.
Embodiment 3
Preparation 1-[2-bis-(trifluoromethyl) amino-1-(4-Trifluoromethoxyphen-l)-ethyl]-hexalin.
Preparation method, with embodiment 1, replaces with iodo trifluoromethane by the methyl iodide in embodiment 1.
Here description of the invention and application is illustrative, not wants scope of the present invention to limit in the above-described embodiments, and therefore, the present invention is not subject to the restriction of the present embodiment, and the technical scheme that any employing equivalence replacement obtains is all in the scope of protection of the invention.

Claims (4)

1.1-[2-dimethylamino-1-(4-p-methoxy-phenyl) ethyl] new derivatives of hexalin, it is characterized in that thering is the following chemical structure general formula:
Figure FDA0000429097720000011
R in formula 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14r 15, R 16, R 17, R 18, R 19be hydrogen or deuterium or fluorine independently, wherein have one at least for deuterium or fluorine.
2. 1-[2-dimethylamino-1-(4-p-methoxy-phenyl as claimed in claim 1) ethyl] new derivatives of hexalin, it is characterized in that R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14r 15, R 16, R 17, R 18, R 19in one or several is fluorine.
3. 1-[2-dimethylamino-1-(4-p-methoxy-phenyl as claimed in claim 1) ethyl] new derivatives of hexalin, it is characterized in that R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, R 13, R 14r 15, R 16, R 17, R 18, R 19in one or several is deuterium.
4. the 1-[2-dimethylamino-1-(4-p-methoxy-phenyl as described in any one in claim 1-3) ethyl] application of new derivatives of hexalin, it is characterized in that the application of described derivative in the medicine of preparing Cure of depression and anxiety disorder disease.
CN201310646191.4A 2013-12-03 2013-12-03 Novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and application thereof Pending CN103772220A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310646191.4A CN103772220A (en) 2013-12-03 2013-12-03 Novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310646191.4A CN103772220A (en) 2013-12-03 2013-12-03 Novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and application thereof

Publications (1)

Publication Number Publication Date
CN103772220A true CN103772220A (en) 2014-05-07

Family

ID=50565049

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310646191.4A Pending CN103772220A (en) 2013-12-03 2013-12-03 Novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and application thereof

Country Status (1)

Country Link
CN (1) CN103772220A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
CN101336226A (en) * 2005-12-01 2008-12-31 奥斯拜客斯制药有限公司 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
CN101663263A (en) * 2007-02-21 2010-03-03 塞普拉柯公司 Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
WO2012070025A1 (en) * 2010-11-26 2012-05-31 Cadila Pharmaceuticals Ltd Process for the preparation of agomelatine
CN102675101A (en) * 2012-05-16 2012-09-19 王蕾 Preparation method of 2-(4-haloethyl) phenyl-2-methyl propionic ester and synthesis method of bilastine
WO2013028639A1 (en) * 2011-08-19 2013-02-28 The Trustees Of Princeton University C-halogen bond formation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
CN101336226A (en) * 2005-12-01 2008-12-31 奥斯拜客斯制药有限公司 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
CN101663263A (en) * 2007-02-21 2010-03-03 塞普拉柯公司 Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
WO2012070025A1 (en) * 2010-11-26 2012-05-31 Cadila Pharmaceuticals Ltd Process for the preparation of agomelatine
WO2013028639A1 (en) * 2011-08-19 2013-02-28 The Trustees Of Princeton University C-halogen bond formation
CN102675101A (en) * 2012-05-16 2012-09-19 王蕾 Preparation method of 2-(4-haloethyl) phenyl-2-methyl propionic ester and synthesis method of bilastine

Similar Documents

Publication Publication Date Title
US20200179336A1 (en) Methods of treating neurological and psychiatric disorders
JP6479670B2 (en) 7,8-Dihydroxyflavone and 7,8-substituted flavone derivatives, compositions and methods related thereto
EP1905757A1 (en) Derivatives of Venlafaxine and methods of preparing and using the same
JPS61277618A (en) Remedy for autism
US20210315859A1 (en) Methods of treating neurological and psychiatric disorders
US11149014B2 (en) Method for treating pain or associated condition or symptom
US9156826B2 (en) Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
JP2005535584A5 (en)
US11332475B2 (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
CN104231013B (en) A kind of gastrodine Glehnilae and preparation method thereof and application
CN104523589A (en) Oral suspension type medicine composition containing agomelatine
CN101270074A (en) Method for preparing high purity mitiglinide calcium
CN111960972A (en) Preparation process and application of taurine magnesium salt and taurine magnesium complex
CN103772220A (en) Novel derivative of 1-[2-dimethylamino-1-(4-methoxyphenyl) ethyl] cyclohexanol and application thereof
CN103724281A (en) Novel derivative of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl and application of novel derivative
CN115141161A (en) Crystal form A of pramipexole xinafoate and preparation method thereof
CN103724198A (en) Novel derivative of dimethyl fumarate and application of novel derivative
RU2015117412A (en) IMPROVED METHOD FOR OBTAINING VINCRISTINE INTEGRATED IN LIPOSOMES FOR THERAPEUTIC USE
CN103819471A (en) Derivative of pyridine and (4,3-d) pyrimidine-1(2H)-base phenyl acetamide and application thereof
CN106176740B (en) The medical usage of the anti-habituation of corydalmine
WO2019034114A1 (en) COMPOSITION CONTAINING L-CARNITINE-β-HYDROXYBUTYRATE AND PREPARATION METHOD THEREOF
CN110339201B (en) Application of polygala tenuifolia saponin B
CN103570669B (en) Brain-targeted O-desmethylvenlafaxine phenolic ester prodrug and preparation method and applications thereof
WO2018213715A1 (en) Methods and compositions for improving sleep
TWI735652B (en) Co-crystal and/or eutectic crystal of kojic acid, compositions comprising the same, and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140507